GLP-1 RA Use Linked to Lower Rates of Hyperkalemia in Type 2 Diabetes
By Elana Gotkine HealthDay Reporter
MONDAY, Aug. 12, 2024 -- Treatment with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with lower rates of hyperkalemia and a lower rate of renin-angiotensin system inhibitor (RASi) discontinuation compared with treatment with dipeptidyl peptidase-4 inhibitors (DPP-4is) among patients with type 2 diabetes (T2D), according to a study published online Aug. 12 in JAMA Internal Medicine.
Tao Huang, from Peking University in Beijing, and colleagues compared rates of hyperkalemia and RASi persistence among new users of GLP-1 RAs versus users of DPP-4is in a cohort study including adults with T2D who initiated GLP-1 RA or DPP-4i treatment between Jan. 1, 2008, and Dec. 31, 2021. Data were included for 33,280 individuals: 13,633 using GLP-1 RAs and 19,647 using DPP-4is.
The median time receiving treatment was 3.9 months. The researchers found that GLP-1 RA use was associated with a lower rate of any hyperkalemia and moderate-to-severe hyperkalemia compared with DPP-4i use (hazard ratios, 0.61 and 0.52, respectively). Overall, 1,381 of the 21,751 participants using RASis discontinued this therapy. GLP-1 RA use was associated with a lower rate of RASi discontinuation compared with DPP-4i use (hazard ratio, 0.89). In intention-to-treat analyses and across strata of age, sex, cardiovascular comorbidity, and baseline kidney function, results were consistent.
"Treatment with GLP-1 RAs may enable wider use of the guideline-recommended cardioprotective and renoprotective medications and contribute to improving clinical outcomes in this population," the authors write.
One author disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Exposure to Trihalomethanes Linked to Chronic Kidney Disease
TUESDAY, July 8, 2025 -- Exposure to trihalomethanes, especially brominated trihalomethanes, in residential community water supplies (CWS) is associated with an increased risk for...
Muscle Ultrasound Can Detect Insulin Resistance
MONDAY, June 30, 2025 -- Muscle ultrasound can detect insulin resistance and lower muscle mass, according to a study published online June 12 in the Journal of Ultrasound...
Disparities Seen in Continuous Glucose Monitor Rx by Language Preference
FRIDAY, June 27, 2025 -- For patients with type 2 diabetes (T2D), disparities in continuous glucose monitor (CGM) prescriptions are seen by language preference, with less access...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.